Xella Health has closed more than $3.7 million in pre-seed funding as it prepares to launch a new women’s precision health and telemedicine platform aimed at helping women better understand their biology across every life stage.
The funding round was led by Precursor Ventures, with participation from Capital F, Ulu Ventures and additional funds, alongside strategic angel investors from the healthcare, diagnostics and consumer technology sectors. The San Francisco-based company said the capital will support final product development, strategic partnerships and its planned Spring 2026 market launch.
Xella Health is positioning itself as a new category within women’s healthcare, moving away from symptom-based treatment and fragmented testing. Instead, the company combines multi-omic diagnostics, longitudinal data and personalised, clinician-led guidance to provide insights across fertility, chronic conditions, hormonal health, early cancer detection and preventative care.
A central part of Xella’s approach is the use of menstrual fluid alongside peripheral blood to access biological signals that have historically been overlooked. According to the company, this enables insights into issues such as menstrual irregularities, chronic pelvic pain, egg quality and quantity, miscarriage risk, perimenopause stage, hormone replacement therapy guidance, genetic predispositions for reproductive cancers and broader ageing indicators.
Despite women accounting for more than half of the global population, Xella said female biology has long been under-researched and inconsistently treated within healthcare systems. The company was founded to challenge this approach and deliver more comprehensive, data-driven care.
Xella was co-founded by Kelly Lacob, CEO, Adriana Dantas, COO, and Jesus Ching, PhD, CTO, all of whom bring experience from organisations including Stanford, Johns Hopkins, Roche, BD, Mammoth Biosciences and Arc Bio.
“Our mission is to give women the answers and care they have always deserved,” said Kelly Lacob, Co-Founder & CEO of Xella. “Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today. Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyze translates into meaningful, actionable health outcomes rather than more noise. This funding allows us to accelerate product development and prepare for our first launch.”
Investor interest has followed growing consumer demand. Ahead of its Spring 2026 launch, Xella is approaching a 10,000-person waitlist, signalling strong interest in a more personalised and preventative approach to women’s healthcare.
“Xella is rethinking women’s health from the ground up—starting with the insight women need to make sense of their own biology over time,” said Ashtan Jordan, Principal at Precursor Ventures.
“Xella represents the future of proactive, personalized care enabled at scale by AI—where early detection can meaningfully change outcomes for women by going after one of the largest unsolved problems in healthcare—early, personalized detection for women,” said Margaret Coblentz, Co-Founder and General Partner at Capital F.
The company has also made several senior hires across marketing, computational biology and software engineering as it prepares for launch.
About Xella Health
Xella Health is redefining women’s healthcare. Our mission: to uncover the root causes behind women’s health concerns—from fertility and perimenopause to endometriosis, PCOS, early cancer detection and beyond. We’re pioneering first-of-its-kind, AI-powered multi-omic testing that makes precision medicine and concierge care accessible to all women.
This is healthcare that finally puts women first—empowering women everywhere to Know Your Code™.
